C4 Therapeutics, Inc. (CCCC)
4.11
+0.11
(+2.75%)
USD |
NASDAQ |
Aug 24, 16:00
4.07
-0.04
(-0.97%)
After-Hours: 20:00
C4 Therapeutics Enterprise Value : 294.82M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 294.82M |
| August 20, 2026 | 298.51M |
| August 19, 2026 | 320.63M |
| August 18, 2026 | 316.94M |
| August 17, 2026 | 327.39M |
| August 14, 2026 | 324.32M |
| August 13, 2026 | 304.65M |
| August 12, 2026 | 282.53M |
| August 11, 2026 | 278.84M |
| August 10, 2026 | 248.11M |
| August 07, 2026 | 261.63M |
| August 06, 2026 | 250.57M |
| August 05, 2026 | 248.11M |
| August 04, 2026 | 246.88M |
| August 03, 2026 | 233.37M |
| July 31, 2026 | 230.91M |
| July 30, 2026 | 253.03M |
| July 29, 2026 | 235.82M |
| July 28, 2026 | 239.51M |
| July 27, 2026 | 244.43M |
| July 24, 2026 | 221.07M |
| July 23, 2026 | 251.80M |
| July 22, 2026 | 262.86M |
| July 21, 2026 | 273.92M |
| July 20, 2026 | 243.20M |
| Date | Value |
|---|---|
| July 17, 2026 | 256.72M |
| July 16, 2026 | 243.20M |
| July 15, 2026 | 270.24M |
| July 14, 2026 | 271.47M |
| July 13, 2026 | 284.99M |
| July 10, 2026 | 302.19M |
| July 09, 2026 | 330.46M |
| July 08, 2026 | 318.17M |
| July 07, 2026 | 337.84M |
| July 06, 2026 | 312.02M |
| July 02, 2026 | 331.69M |
| July 01, 2026 | 336.61M |
| June 30, 2026 | 377.17M |
| June 29, 2026 | 275.33M |
| June 26, 2026 | 265.97M |
| June 25, 2026 | 280.54M |
| June 24, 2026 | 264.93M |
| June 23, 2026 | 261.81M |
| June 22, 2026 | 251.41M |
| June 18, 2026 | 254.53M |
| June 17, 2026 | 230.60M |
| June 16, 2026 | 222.28M |
| June 15, 2026 | 220.20M |
| June 12, 2026 | 228.52M |
| June 11, 2026 | 225.40M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cartesian Therapeutics, Inc. | 217.83M |
| Beam Therapeutics, Inc. | 2.168B |
| Rallybio Corp. | -3.534M |
| Q32 Bio, Inc. | 278.10M |
| Arrowhead Pharmaceuticals, Inc. | 12.07B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.64M |
| Revenue (Quarterly) | 6.641M |
| Total Expenses (Quarterly) | 30.28M |
| EPS Diluted (Quarterly) | -0.1808 |
| Gross Profit Margin (Quarterly) | 73.05% |
| Profit Margin (Quarterly) | -355.9% |
| Earnings Yield | -24.30% |
| Normalized Earnings Yield | -21.78 |